Brief: Entrada Therapeutics Announces Clinical Hold On Ind Application For Entr-601-44 In Duchenne Muscular Dystrophy
19/12/2022 21:31
Dec 19 (Reuters) - Entrada Therapeutics Inc TRDA.O :
* ENTRADA THERAPEUTICS ANNOUNCES CLINICAL HOLD ON IND
APPLICATION
FOR ENTR-601-44 IN DUCHENNE MUSCULAR DYSTROPHY
* ENTRADA THERAPEUTICS INC - FDA INDICATED THEY WILL PROVIDE
AN
OFFICIAL CLINICAL HOLD LETTER TO ENTRADA WITHIN 30 DAYS
Source text for Eikon: ID:nGNXbPHm7x
Further company coverage: TRDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entrada Therapeutics
See all newsBrief: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Entrada Therapeutics Q2 Collaboration Revenue USD 898 Thousand
Entrada Therapeutics Q2 net loss narrows on lower costs
Entrada Therapeutics Inc expected to post a loss of $1.05 a share - Earnings Preview